Aquestive Therapeutics, Inc. Net Change in Cash
Aquestive Therapeutics, Inc. (AQST) reported Net Change in Cash of -$22.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$10.44M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$2.89M, a 104.05% decline year-over-year.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $71.33M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$391.00K.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $49.62M, a 4.09% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $47.67M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$3.40M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$751.00K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.68M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$10.44M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $49.62M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $57.52M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$11.01M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$2.89M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $47.67M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $54.02M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $66.00M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $71.33M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$3.40M 10-K · filed 2025-03-05 | |||
| 2023-09-30 | -$2.36M 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | -$4.84M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$391.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$751.00K 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$9.38M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$10.33M 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | -$13.29M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | -$3.78M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$643.00K 10-Q · filed 2022-11-01 | |||
| 2021-06-30 | $2.43M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$4.31M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | -$17.52M 10-K · filed 2022-03-08 | |||
| 2020-09-30 | -$32.26M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | -$23.90M 10-Q · filed 2021-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |